Table 1.
Ongoing clinical trials of surfactant therapy for COVID-19.
| NCT | Preparation | Conditions | Primary purpose | Intervention | Status |
|---|---|---|---|---|---|
| NCT04384731 | CUROSURF® (Poractant alfa) | COVID-19, ARDS | Design a new administration protocol for surfactant replacement therapy in adults, to be tested in COVID-19 adult ARDS patients. | Patient receiving surfactant (48 mg/kg) administered by bronchial fibroscopy. The total volume was divided in each of the five lobar bronchi. | Phase II |
| NCT04502433 | CUROSURF® (Poractant alfa) | COVID-19, ARDS | Evaluate the efficacy and safety of poractant alfa, administered by endotracheal instillation in adult hospitalized patients with SARS-COV-19 ARDS. | Three administrations with a 24 h dosing interval. Each endotracheal administration will consist of poractant alfa bolus: 30 mg/kg Lean Body Weight. | Phase II |
| NCT04375735 | Bovine Lipid Extract Surfactant (BLES) | COVID-19, ARDS | Improve the mortality of mechanically ventilated COVID-19 patients. The primary goal is to first determine feasibility and safety. | BLES was administered in doses of 50 mg/kg ideal bodyweight, at a concentration of 27 mg/mL so a total volume of approximately 2 mL/kg was administered. The material was instilled via the suction catheter. | Phase II |
| NCT04389671 | Lucinactant Sinapultide (KL4) Surfactant | COVID-19, Acute Lung Injury, ARDS | Evaluate whether Lucinactant can improve the acute lung injury and ARDS of COVID-19 patients. | Lucinactant administered as a liquid at a dose of 80 mg total phospholipids/kg Lean Body Weight. | Phase II |
| NCT04362059 | COVSurf Drug | Respiratory Infections | Evaluate the delivery of surfactant in patient lungs using the COVSurf Drug Delivery System. | COVSurf Drug Delivery System. | Not Applicable |
| NCT04847375 | Exogenous surfactant | COVID-19, ARDS | Evaluate effect of exogenous nebulized surfactant in the pre-intubation stages of the disease. | Nebulized surfactant was administered by face mask with a nebulizer. | Not Applicable |
| NCT04659122 | AT-100 (rhSP-D) | COVID-19 | Determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe COVID-19. | Reconstituted AT-100 for intratracheal administration. | Phase I |